FDA-approved medication information

FDA-approved product exists

Tesamorelin

FDA approval belongs to Egrifta products and their specific labeled indication. ASR discusses only FDA-approved products when clinically appropriate and available.

A transparent starting point

What to know about Tesamorelin

This page is educational and does not recommend a medication. ASR offers only FDA-approved products; a clinician confirms the exact product, labeled use, availability, and individual suitability.

FDA and compounding status

FDA approval belongs to Egrifta products and their specific labeled indication. ASR discusses only FDA-approved products when clinically appropriate and available.

FDA approval applies to the exact approved product. Compounded drugs are not FDA-approved and are not ASR peptide offerings.

Evidence and limitations

Research quality, studied populations, dosing, formulation, and route can differ. Results cannot be guaranteed, and findings about one product or route should not be applied automatically to another.

Risks and monitoring

Potential side effects, contraindications, interactions, pregnancy and breastfeeding considerations, storage, dosing, and follow-up depend on the exact product and the patient's health history. A clinician reviews these topics before FDA-approved treatment.

Primary regulatory references Search current FDA-approved products in Drugs@FDA → Read FDA compounding questions and answers →